HKeyBio Industry Commentary

VAV1: A Breakthrough in Targeting a Challenging Autoimmune Disease Protein

Autoimmune Targets & Models Series | Issue 32

Originally published in Chinese on July 10, 2025. This commentary reflects information available as of July 10, 2025.

VAV1 integrates immune-receptor signaling through both guanine nucleotide exchange factor (GEF)-dependent activity and GEF-independent scaffolding functions. Targeted degradation offers a potential way to modulate this difficult-to-drug signaling node. This article reviews its biology, the early development of MRT-6160, and relevant preclinical disease models.

Reading guide

01 VAV1 target overview

02 Mechanisms of VAV1 signaling

03 Progress in VAV1-directed drug development

04 Potential indications and relevant preclinical models

01 VAV1 Target Overview

VAV1 (Vav guanine nucleotide exchange factor 1) is a member of the VAV family, alongside VAV2 and VAV3. The human VAV1 gene is located at chromosome 19p13.3. VAV1 is expressed predominantly in hematopoietic lineages, including T cells, B cells and macrophages. Its defining feature is dual functionality: it activates Rho-family GTPases such as RAC1 through its GEF activity and also acts as a scaffold that helps assemble signaling complexes. These complementary functions make VAV1 a central coordinator of immune-cell activation. [3]

02 Mechanisms of VAV1 Signaling

VAV1 contributes to the development, activation, and functional regulation of both T cells and B cells. This dual role makes it a potential autoimmune disease target for modulating T- and B-cell responses together.

T-Cell Receptor Signaling

Following T-cell receptor (TCR)/CD3 engagement, LCK-mediated phosphorylation supports ZAP70 activation and the assembly of signaling complexes containing LAT and SLP-76. VAV1 interacts with SLP-76 and other components through its SH2 and SH3 domains. Its GEF activity activates RAC1 and related Rho-family GTPases. In parallel, VAV1’s scaffolding functions help coordinate receptor-proximal signaling, including PLCγ1-linked calcium and protein kinase C (PKC) pathways. The resulting network activates transcription factors including NFAT, NF-κB, and AP-1, regulating T-cell proliferation, differentiation, and cytokine production. These are interconnected branches rather than a single linear GEF–RAC1–PLCγ1 pathway. [4]

B-Cell Receptor Signaling

B-cell receptor (BCR) engagement activates proximal kinases including LYN and SYK and recruits adaptors such as BLNK/SLP-65. VAV1 participates in signaling complexes containing SLP-65, BTK, and GRB2. Its GEF-dependent activation of RAC1 and related GTPases, together with adaptor functions, helps coordinate BCR responses involving PLCγ2-linked calcium signaling, PKC, and mitogen-activated protein kinases (MAPKs). Downstream transcription factors, including NFAT and NF-κB, influence B-cell activation, proliferation, antibody production, and immune responses. The contributions of VAV1 and other VAV-family members vary with cell type and signaling context. [5]

Together, VAV1’s GEF-dependent activation of Rho-family GTPases and its GEF-independent scaffolding functions integrate and transmit signals that regulate T- and B-cell immune responses.

 Figure 1. VAV1 in T- and B-cell receptor signaling. From Neurath and Berg [1], Figure 1. © 2024 The Authors; Elsevier. CC BY-NC-ND 4.0.

03 Progress in VAV1-Directed Drug Development

VAV1 has long been a challenging drug target. Its multidomain structure combines GEF activity with scaffolding functions, it lacks an obvious conventional small-molecule binding pocket, and it shares substantial homology with other VAV-family members. MRT-6160 has opened a new route through these barriers by selectively degrading the protein.

Table 1. VAV1-directed drug pipeline at the time of the original article.

Developed by Monte Rosa Therapeutics, MRT-6160 is described as a first-in-class selective VAV1 molecular glue degrader. It acts downstream of T- and B-cell receptors and can reduce pro-inflammatory cytokines involved in autoimmunity. In October 2024, Monte Rosa entered into an exclusive global development and commercialization license agreement with Novartis for VAV1 degraders, including MRT-6160. The terms comprised a $150 million upfront payment and up to $2.1 billion in potential development, regulatory, and sales milestones, a potential total of $2.25 billion before royalties and profit sharing. Novartis obtained worldwide rights and responsibility for development from Phase 2 onward; Monte Rosa retained responsibility for the Phase 1 study. [6]

 Figure 2. MRT-6160 in a T-cell transfer model of colitis: colon histology and cytokine readouts. Monte Rosa Therapeutics corporate presentation [8]; the supplied image was credited to “Xin Yao Lie Ren Bi Ji”. © Monte Rosa Therapeutics.

Preclinical studies reported significant reductions in disease activity in a T-cell transfer model of colitis and a collagen-induced arthritis (CIA) model. Oral MRT-6160 rapidly degraded VAV1 in vivo in relation to drug exposure, while cellular studies showed concentration-dependent effects on immune-cell activation and effector functions. [2,9] These results support substantial therapeutic potential across autoimmune and inflammatory diseases, including rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, and psoriasis. With further development and clinical validation, this approach could provide new treatment options for patients; efficacy in these human diseases had not been established at the time of the original article.

 Figure 3. MRT-6160 in a CIA model in DBA/1 mice: clinical scores, joint histology, and histopathology scores. From the Monte Rosa Therapeutics ACR 2023 poster associated with Cartwright et al. [2]. © Monte Rosa Therapeutics.

04 Potential Indications and Relevant Preclinical Models

VAV1-directed strategies may have broad applicability across T- and/or B-cell-mediated autoimmune and inflammatory diseases, potentially extending to many of the conditions shown in Figure 4. This is a therapeutic hypothesis across indications, rather than evidence that VAV1 degradation is clinically effective in every condition.

Autoimmune diseases. Examples include rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), ulcerative colitis (UC), and Crohn’s disease (CD).

Chronic inflammatory diseases. Examples include psoriasis, ankylosing spondylitis, and juvenile idiopathic arthritis.

 Figure 4. Potential indication landscape for VAV1-directed therapies. From Neurath and Berg [1], Figure 3; drug-class approval and investigation symbols reflect that 2024 publication. Question marks denote proposed VAV1 potential. © 2024 The Authors; Elsevier. CC BY-NC-ND 4.0.

HKeyBio develops models across multiple species, strains, mechanisms, and disease subtypes. Its portfolio includes models relevant to the diseases discussed above, offering preclinical researchers a broad choice of tools aligned with target biology and clinical translation. Available animal models include the following:

Table 2. Relevant autoimmune disease models offered by HKeyBio.

Abbreviations: IMQ, imiquimod; IL, interleukin; NHP, nonhuman primate; DSS, dextran sulfate sodium; TNBS, 2,4,6-trinitrobenzenesulfonic acid; TLR7, Toll-like receptor 7; AChR, acetylcholine receptor. These are representative disease models; candidate-specific target engagement and suitability require confirmation.

Representative Model Data

Psoriasis (Pso)

Psoriasis is a skin disease that causes a rash with itchy, scaly plaques, commonly affecting the knees, elbows, trunk, and scalp. In plaque psoriasis, accelerated skin-cell turnover produces dry, scaly plaques.

 Figure 5. IMQ-induced psoriasis model in cynomolgus macaques. HKeyBio example data: skin appearance, PASI score, histopathology, and skin IL-17/IL-36 measurements.

Systemic Lupus Erythematosus (SLE)

SLE is a complex, heterogeneous disease characterized by autoantibody production and immune-complex deposition, followed by target-tissue damage. It is the condition most people refer to as “lupus.” Common symptoms include skin rash, joint pain or swelling (arthritis), swelling of the feet and around the eyes, often due to kidney involvement, extreme fatigue, and low-grade fever.

 Figure 6. TLR7 agonist-induced SLE-like model in cynomolgus macaques. HKeyBio example data: anti-dsDNA antibodies, skin IFN-α, urinary protein, and histopathology.

 Figure 7. TLR7 agonist-induced SLE-like model in C57BL/6 mice. HKeyBio example data: body weight, spleen weight, serum antibodies, splenic immune-cell populations, and kidney histopathology.

Inflammatory Bowel Disease (IBD)

IBD encompasses a complex group of diseases characterized by long-term inflammation of the gastrointestinal tract. Its two main forms are ulcerative colitis and Crohn’s disease.

 Figure 8. DSS-induced colitis model in nonhuman primates. HKeyBio example data: disease activity index (DAI), endoscopic index, colon anatomy, and histopathology scores.

 Figure 9. DSS-induced chronic colitis model in C57BL/6 mice. HKeyBio example data: body weight, colon length and weight, DAI, colon weight-to-length ratio, and histopathology score.

Rheumatoid Arthritis (RA)

RA is an autoimmune disease. Collagen-induced arthritis is an experimental autoimmune model induced by immunization with type II collagen, a major component of articular cartilage, in susceptible rodents, including rats and mice, and in nonhuman primates. Following immunization, animals develop autoimmune polyarthritis that shares multiple clinical and histological features with human RA.

 Figure 10. Collagen-induced arthritis model in cynomolgus macaques. HKeyBio example data: body weight, clinical score, serum ALP/CRP, and anti-collagen IgG.

 Figure 11. CIA model in DBA/1 mice. HKeyBio example data: body weight, clinical score, serum CRP, joint IL-6, and joint histology.

HKeyBio also provides customized models to meet specific research needs. We welcome opportunities to support autoimmune drug development and invite researchers to contact us to discuss their projects.

References

[1] Neurath MF, Berg LJ. VAV1 as a putative therapeutic target in autoimmune and chronic inflammatory diseases. Trends Immunol. 2024;45(8):580–596. Source

[2] Cartwright A, et al. A VAV1-directed molecular glue degrader, MRT-6160, reduces joint inflammation in a collagen-induced arthritis autoimmune disease model. Arthritis Rheumatol. 2023;75(suppl 9). Conference abstract and associated ACR 2023 poster. Source

[3] Human Protein Atlas. VAV1 gene information. Chromosome 19, cytoband p13.3; Ensembl gene ENSG00000141968; NCBI Gene 7409. Source

[4] Saveliev A, Vanes L, Ksionda O, et al. Function of the nucleotide exchange activity of Vav1 in T cell development and activation. Sci Signal. 2009;2:ra83. Source

[5] Löber J, Hitzing C, Münchhalfen M, Engels N. Vav family proteins constitute disparate branching points for distinct BCR signaling pathways. Eur J Immunol. 2020;50:1912–1928. Source

[6] Monte Rosa Therapeutics. Global license agreement with Novartis to advance T- and B-cell-modulating VAV1-directed molecular glue degraders. October 28, 2024. Source

[7] Monte Rosa Therapeutics. First quarter 2025 financial results and business updates. May 8, 2025. Source

[8] Monte Rosa Therapeutics. Corporate presentation filed with the U.S. Securities and Exchange Commission, January 2025; slide 41 contains the colitis histology and cytokine panels corresponding to Figure 2. Source

[9] Cartwright A, et al. P164: MRT-6160, a VAV1-directed molecular glue degrader, inhibits disease progression and inflammation in a T-cell transfer model of colitis. J Crohns Colitis. 2024;18(suppl 1):i464. Conference abstract. Source

About HKeyBio

HKeyBio, the autoimmune disease model specialist, is a preclinical contract research organization (CRO) focused on in vivo efficacy services for autoimmune disease. Its core technical team has more than 20 years of experience in autoimmune drug development. The company operates molecular, cellular, pathology, small-animal, and analytical testing facilities in Suzhou Industrial Park, together with nonhuman primate research sites in Guangxi and Suzhou. It has nearly 60 employees, with project leaders holding master’s or doctoral degrees. The team has experience supporting more than 300 investigational new drug (IND) applications and specializes in addressing complex challenges during autoimmune drug development and regulatory submission.

· 20+ NHP models of autoimmune disease

· 200+ animal models of autoimmune disease

· Experience supporting 300+ IND applications in autoimmune diseases

Disclaimer. This article is provided for reference and does not constitute investment advice. Investors who act on it do so at their own risk. The publisher takes no position on the statements and judgments presented and makes no express or implied warranty regarding the accuracy, reliability, or completeness of the content. Readers should use it for reference and assume responsibility for their own decisions. Articles are shared for informational purposes. If any content infringes your rights, please contact us and we will remove it.